title: Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: A comparative assessment.
abstract: THE OBJECTIVE OF WORK WAS TO FORMULATE, EVALUATE AND COMPARE THE TRANSDERMAL POTENTIAL OF NOVEL VESICULAR NANOCARRIERS: ethosomes and ultradeformable liposomes, containing clotrimazole (CLT), an anti-fungal bioactive. The ethosomal formulation (ET4) and ultradeformable liposomal (UL) formulation (TT3) showed highest entrapment 68.73 ± 1.4% and 55.51 ± 1.7%, optimal nanometric size range 132 ± 9.5 nm and 121 ± 9.7 nm, and smallest polydispersity index 0.027 ± 0.011 and 0.067 ± 0.009, respectively. The formulation ET4 provided enhanced transdermal flux 56.25 ± 5.49 μg/cm(2)/h and decreased the lag time of 0.9 h in comparison to TT3 formulation (50.16 ± 3.84 μg/cm(2)/h; 1.0 h). Skin interaction and FT-IR studies revealed greater penetration enhancing effect of ET4 than TT3 formulation. ET4 formulation also had the highest zone of inhibition (34.6 ± 0.57 mm), in contrast to TT3 formulation (29.6 ± 0.57 mm) and marketed cream formulation (19.0 ± 1.00 mm) against candidal species. Results suggested ethosomes to be the most proficient carrier system for dermal and transdermal delivery of clotrimazole.
authors: College of Pharmacy, IPS Academy, A.B. Road, Indore 452012, MP, India.
authors: Rahul G S
authors: RG
authors: Maheshwari
authors: Rakesh K
authors: RK
authors: Tekade
authors: Piyoosh A
authors: PA
authors: Sharma
authors: Gajanan
authors: G
authors: Darwhekar
authors: Abhishek
authors: A
authors: Tyagi
authors: Rakesh P
authors: RP
authors: Patel
authors: Dinesh K
authors: DK
authors: Jain
keywords: Anticandidal efficiency; Atomic force microscopy; Ethosomes; Nanocarriers; Ultradeformable liposomes
references: Int J Antimicrob Agents. 2002 Nov;20(5):375-9
references: 12431873
references: Toxicol In Vitro. 2007 Dec;21(8):1505-12
references: 17703912
references: J Control Release. 2004 Mar 24;95(3):535-46
references: 15023464
references: Biochim Biophys Acta. 1996 Dec 13;1304(3):179-89
references: 8982264
references: J Control Release. 2007 Nov 6;123(2):148-54
references: 17884226
references: Int J Pharm. 2001 May 21;219(1-2):95-105
references: 11337170
references: J Control Release. 2000 Apr 3;65(3):403-18
references: 10699298
references: Int J Pharm. 2005 Sep 14;301(1-2):268-76
references: 16023808
references: Int J Pharm. 2006 Sep 28;322(1-2):60-6
references: 16806755
references: Int J Pharm. 2007 Mar 6;332(1-2):1-16
references: 17222523
references: Colloids Surf B Biointerfaces. 2008 Jul 15;64(2):200-7
references: 18378125
references: J Control Release. 2003 Dec 12;93(3):377-87
references: 14644587
references: Int J Pharm. 2005 Sep 14;301(1-2):140-8
references: 16024188
references: Vaccine. 1998 Jan-Feb;16(2-3):188-95
references: 9607029
references: Biochim Biophys Acta. 2002 Aug 19;1564(1):21-30
references: 12100992
references: Int J Pharm. 2007 Aug 1;340(1-2):13-9
references: 17446015
references: Int J Pharm. 2005 Jul 14;298(1):1-12
references: 15896932
references: Talanta. 2007 Aug 15;73(1):12-22
references: 19071844
references: AAPS PharmSciTech. 2007 Dec 21;8(4):E111
references: 18181532
references: Anal Biochem. 1977 Oct;82(2):376-84
references: 562078
references: Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1999 Feb;122(2):205-10
references: 10190046
references: Pharm Res. 2000 Nov;17(11):1354-9
references: 11205727
references: J Control Release. 2006 Nov 28;116(2):e107-9
references: 17718942
references: J Control Release. 2005 Aug 18;106(1-2):99-110
references: 15935505
references: Biomaterials. 2006 Jun;27(18):3491-6
references: 16513163
references: Eur J Pharm Biopharm. 1999 Nov;48(3):217-24
references: 10612032
references: Obstet Gynecol. 1995 Dec;86(6):925-30
references: 7501341
references: Clin Microbiol Rev. 1999 Jan;12(1):147-79
references: 9880479
references: Anal Biochem. 1978 Oct 15;90(2):809-15
references: 727510
references: Eur J Pharm Biopharm. 2007 Sep;67(2):398-405
references: 17452098
references: J Pharm Biomed Anal. 2000 Mar;22(2):363-76
references: 10719920